2 Growth Stocks to Buy in October

With the 10-Year Treasury yield hovering near 5.3%, its highest level since 2007, it might seem like a bad time to buy high-growth stocks. Rising yields compress a higher-growth company's future earnings, and they drive investors toward fixed-income investments like T-bills and CDs.

But if you can tune out that near-term noise and plan to hold your stocks for at least a few years, it's still a smart move to increase your exposure to higher-growth companies. Let's take a look at two of those stocks -- Grail (NASDAQ: GRAL) and Veeva Systems (NYSE: VEEV) -- and see why they're still worth buying even as the macro headwinds rattle the broader market.

Image source: Getty Images.

Grail

Grail sells Galleri, a blood test that aims to detect dozens of cancers before any symptoms appear. The FDA hasn't approved Galleri yet, but Grail already sells it to independent customers, some businesses, and hospital pilot programs on a cash-only basis for about $949.

Through those cash-only sales, Grail grew its revenue from $93 million in 2023 to $147 million in 2025. In the first half of 2026, its total test volume surged 42% year over year to 117,000. For the full year, analysts expect its revenue to rise 23% to $181 million.

Grail suffered a setback earlier this year when its largest NHS England trial failed to meet its primary endpoint. But in late September, an FDA panel endorsed a premarket approval for Galleri based on its safety, efficacy, and potential benefits. Those endorsements were non-binding, but they suggest Galleri could receive a premarket approval in 2027.

If the FDA approves Galleri, Grail's total addressable market would instantly expand through private insurance and Medicare plans. Even though its stock seems expensive at 33 times this year's sales, it has the potential to deliver multibagger gains over the next few years.

Veeva

Veeva provides cloud-based customer relationship management (CRM) services for the life sciences market. It serves more than 1,500 customers globally, including Eli Lilly, Pfizer, Merck, and AstraZeneca.

Veeva's software enables those companies to track their customer relationships, store and analyze their test data, and monitor the latest clinical trials and industry regulations. It established a first-mover advantage in this niche market and doesn't face any major competitors, so it still has plenty of pricing power and long-term growth potential.

From 2025 to 2028, analysts expect Veeva's revenue and EPS to grow at CAGRs of 13% and 16%, respectively. It might not seem cheap at 39 times next year's earnings. Still, its dominance of the life sciences CRM market -- and the intensifying competition among its clients that will fuel greater demand for its services -- should justify the higher valuation.

Leo Sun has positions in Pfizer. The Motley Fool has positions in and recommends AstraZeneca Plc, Eli Lilly, Merck, Pfizer, and Veeva Systems. The Motley Fool recommends Grail. The Motley Fool has a disclosure policy.